Fingolimod reduces the risk of recurrence of disease activity during the first 12 months after natalizumab discontinuation in multiple sclerosis

被引：0
|
作者：
Havla, J.
Tackenberg, B.
Hellwig, K.
Meinl, I.
Krumbholz, M.
Seitz, F.
Eienbroecker, C.
Gold, R.
Hohlfeld, R.
Kleiter, I.
Kuempfel, T.
机构：
[1] Univ Munich, Munich, Germany
[2] Univ Marburg, Marburg, Germany
[3] Ruhr Univ Bochum, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [1] Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis
    Havla, Joachim
    Tackenberg, Bjorn
    Hellwig, Kerstin
    Krumbholz, Markus
    Meinl, Ingrid
    Seitz, Florian
    Eienbroecker, Christian
    Gold, Ralf
    Hohlfeld, Reinhard
    Kleiter, Ingo
    Kuempfel, Tania
    NEUROLOGY, 2013, 80
  • [2] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Joachim Havla
    Björn Tackenberg
    Kerstin Hellwig
    Ingrid Meinl
    Markus Krumbholz
    Florian Seitz
    Christian Eienbröker
    Ralf Gold
    Reinhard Hohlfeld
    Ingo Kleiter
    Tania Kümpfel
    Journal of Neurology, 2013, 260 : 1382 - 1387
  • [3] Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
    Havla, Joachim
    Tackenberg, Bjoern
    Hellwig, Kerstin
    Meinl, Ingrid
    Krumbholz, Markus
    Seitz, Florian
    Eienbroeker, Christian
    Gold, Ralf
    Hohlfeld, Reinhard
    Kleiter, Ingo
    Kuempfel, Tania
    JOURNAL OF NEUROLOGY, 2013, 260 (05) : 1382 - 1387
  • [4] Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
    Meinl, Ingrid
    Havla, Joachim
    Hohlfeld, Reinhard
    Kuempfel, Tania
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (07) : 991 - 994
  • [5] Disease activity after natalizumab discontinuation in multiple sclerosis: reactivation or rebound?
    Borriello, G.
    Prosperini, L.
    Mancinelli, C.
    Fubelli, F.
    Gianni, C.
    Marinelli, F.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S228 - S228
  • [6] IRIS in a Multiple Sclerosis Patient after Discontinuation of Natalizumab and Newly Started on Fingolimod
    Tomas, Erica
    Wall, Anastacia
    Malik, Amer
    Jung-Henson, Lily
    NEUROLOGY, 2012, 78
  • [7] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, E.
    Schoof, L.
    Hogenboom, L.
    Wessels, M.
    van Ruyven, P.
    van Samkar, A.
    Mostert, J.
    van Kempen, Z.
    van Oosten, B. W.
    Wokke, B. H.
    Tallantyre, E.
    Myhr, K. M.
    Torkildsen, O.
    Killestein, J.
    Smets, I.
    Strijbis, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [8] The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
    Coerver, Eline
    Schoof, Lisa
    Hogenboom, Laura
    Wessels, Mark
    van Ruyven, Paula
    van Samkar, Anusha
    Mostert, Jop
    van Kempen, Zoe
    van Oosten, Bob
    Wokke, Beatrijs
    Tallantyre, Emma
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Killestein, Joep
    Smets, Ide
    Strijbis, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1063 - 1064
  • [9] Cessation of Natalizumab in Multiple Sclerosis and Risk for Relapse Activity within the First 6 Months
    Haas, Judith
    Ebner, Stephanie
    NEUROLOGY, 2012, 78
  • [10] Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
    Daelman, L.
    Maitrot, A.
    Maarouf, A.
    Chaunu, M. P.
    Papeix, C.
    Tourbah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1647 - 1649
12345